Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search

Support for Neuroscience Breakthroughs

Advancing CNS research with smarter clinical trials

pattern_standard
She felt like the weight of the trial was
on her shoulders. Then she found Rho.
Let’s talk

The Neural Network Nexus:
Untangling the Complexity of CNS Trials

Every breakthrough starts with a question: How can we push science forward? Neurological and psychiatric disorders don’t just affect individuals—they impact families, caregivers, and entire communities. Behind every study is a person searching for relief, for progress, for a future that looks different from today. As a neuroscience CRO, Rho begins with those human stories. We bring together CNS research experience, connected teams, and a commitment to smarter, more compassionate clinical trials that make a real difference.

why_rho_img

Why Rho?

Why Rho?

Partner aligned
Our CNS experts work alongside you to advance science, improve outcomes, and help you reach more patients with better therapies.
Thoughtful study design
We craft protocols that respect the complexities of neurological and psychiatric disorders and the patients who live with them.
Innovative data insights
We leverage biomarkers, imaging, and digital data capture to get to the answers faster and more effectively.
Patient-first approach
From recruitment to retention, we focus on building trials that work for people, not just data points.
Neurology and Psychiatry - SPOTLIGHT

Spotlight: Advancing Neurology and Psychiatry Research

In the past five years, we’ve supported more than 90 neurology and psychiatry studies across 840+ sites, including work in Parkinson’s, Alzheimer’s, Multiple Sclerosis, MDD, ADHD, and substance use disorders. Our teams have guided programs from first-in-human to regulatory submission, including in rare and complex conditions.

These trials aren’t easy. We’ve helped launch more than 440 neurology sites and 400 psychiatry sites, enrolling over 6,500 participants—all while keeping timelines and expectations aligned.

But what matters most is the people behind those numbers. We collaborate closely with patient advocacy groups like the Michael J. Fox Foundation, Parkinson’s Foundation, and Davis Phinney Foundation to stay grounded in what matters most: research that’s not just scientifically sound, but truly centered on people.

Neurology and Psychiatry - SPOTLIGHT

Spotlight: Advancing Neurology and Psychiatry Research

In the past five years, we’ve supported more than 90 neurology and psychiatry studies across 840+ sites, including work in Parkinson’s, Alzheimer’s, MDD, ADHD, and substance use disorders. Our teams have guided programs from first-in-human to regulatory submission, including in rare and complex conditions.

These trials aren’t easy. We’ve helped launch more than 440 neurology sites and 400 psychiatry sites, enrolling over 6,500 participants—all while keeping timelines and expectations aligned.

But what matters most is the people behind those numbers. We collaborate closely with groups like the Michael J. Fox Foundation, Parkinson’s Foundation, and Davis Phinney Foundation to stay grounded in what matters most: research that’s not just scientifically sound, but truly centered on people.

Neurology and Psychiatry FAQ

What should sponsors look for in a neuroscience CRO?
Sponsors should look for a neuroscience CRO with deep CNS experience, strong site relationships and knowledge, thoughtful study design, and the ability to connect clinical, regulatory, biometrics, and operational teams around the realities of patients and caregivers. Rho integrates those perspectives to form true partnerships with sponsors to help design and deliver smarter neurology and psychiatry trials.
Rho has extensive experience in clinical trials for movement disorders, neurodegenerative diseases, neuroimmunological disorders, psychiatric conditions, and rare CNS diseases. Our expertise spans Parkinson’s disease, Alzheimer’s disease, MS, depression, schizophrenia, substance use disorders, and more.
Neurology and psychiatry trials often require specialized outcome measures, biomarker validation, and patient recruitment strategies for complex conditions. Rho’s deep expertise in CNS research helps sponsors navigate these complexities successfully.
Recruiting for neurological and psychiatric trials can be difficult due to strict inclusion criteria and long trial durations. Rho leverages targeted site selection, patient engagement strategies, and digital recruitment tools to enhance enrollment. Our deep knowledge of sites allows us to target sites with a history of rapid startup and recruitment.
Yes. Our team has worked on numerous rare CNS disease trials, including those requiring innovative trial designs and regulatory pathways for orphan drug development.

Parkinson’s disease trials designed for real people.

When studies span years, your execution must hold steady. Rho aligns operations to honor the commitment patients, caregivers, and investigators make together.

Parkinson’s disease
Click Here

Comprehensive support for neurology
and psychiatry trials

We provide full-service support for clinical trials across a wide range of CNS conditions:
Neurodegenerative diseases
Advancing research in Alzheimer’s, Parkinson’s, ALS, and related conditions.
Movement disorders
Expertise in Parkinson’s, dystonia, tremor, Huntington’s disease, and other motor dysfunctions.
Psychiatric and mood disorders
Shaping research strategies for trials in depression, schizophrenia, anxiety, substance use disorders, and PTSD.
Rare neurological conditions
Specialized experience in complex, low-prevalence disorders.
CNS biomarkers and imaging
Leveraging cutting-edge tools to enhance trial outcomes.

Meet the
team
who make
it happen

Andrew Feigin

Chief Medical Officer

Brett Gordon

Vice President, Project Delivery

More neuroscience insights from Rho

The Real-World Dynamics Dilemma

Six challenges in acute pain trials and one differentiator—coordinated execution We’ve all been there before. Your acute

Read More
Blog
The Assumption-Reality Paradox

Acute pain trials start with assumptions. How you execute—when reality sets in—determines the outcome. When you’re designing

Read More
Blog
Regulatory Friction You Don’t See Coming in Clinical Development

Early in clinical development, it’s easy to focus on what’s directly in front of you. After all,

Read More
Blog
Parkinson’s Disease Trial Readiness Diagnostic

Parkinson’s disease trials are not only complex studies, but they are long, personal commitments for every patient,

Read More
Guides
The Acute Pain Uncertainty Principle

How confident are you that your acute pain study will behave the way it’s designed to? In

Read More
Guides
When Early Decisions Shape Late-Stage Risk

Early clinical decisions shape regulatory risk and the path to approval   Assumptions about study design and

Read More
Blog

Ready to change lives together?
Behind every trial is a person waiting for progress. Let’s move science forward with purpose and heart.

Let’s talk
Footer_CTA_Partner2
Scroll to Top
Andrew_Feigin-min

Andrew Feigin, MD

Dr. Feigin is Chief Medical Officer and a leading neurologist who brings 30 years of scientific excellence to Rho. A pioneer in clinical research, he’s led over 30 trials as site principal investigator and established renowned clinical trial programs for Parkinson’s, Huntington’s, Tourette syndrome, and other movement disorders. At Rho, he brings sharp insight and strategic savvy to the trials our team supports to maintain safety, integrity, and scientific rigor. Dr. Feigin is passionate about collaboration and innovation and sees Rho as the partner with the special combination of brainpower, quality, and teamwork to make an impact where it matters most.

Brett Gordon

With 25+ years of industry experience, Mr. Gordon has seen just about everything in clinical development. He can balance big-picture thinking with project level precision, which he combines with his knack for building strong relationships. Through operational strategy and executive level oversight, Mr. Gordon supports teams to ensure high-quality and timely program delivery. While he has background in CNS and pain trials, ADHD is where he has really left his mark, providing oversight of trial programs for at least 5 compounds. Mr. Gordon understands that clinical research can get complicated—but he makes it feel doable.